Stocks to BUY, SELL or HOLD Today: Kfin Tech, BEL, Fortis Healthcare, NBCC, Titagarh Rail and more

1 hour ago 22

Stocks to BUY, SELL or HOLD Today

No stock data available

Stocks to BUY, SELL or HOLD Today: Investors are closely monitoring the latest stock recommendations as brokers update their ratings and target prices. Leading firms like Citi, Elara Capital, Goldman Sachs, and Nuvama have issued new guidance on top stocks, helping investors decide which shares to buy, sell, or hold.

A Buy rating signals potential upside, a Sell rating warns of possible underperformance, and a Hold rating suggests maintaining current positions. Key updates include Kfin Technologies, Fortis Healthcare, Bharat Electronics (BEL), and CE Info Systems. Staying informed on these ratings and targets helps investors make timely, strategic decisions.

Here's a list of stocks to BUY, SELL or HOLD today (February 17):

CompanyBrokerageRatingTarget Price (Rs)
Kfin TechnologiesCitiBuy1,385
Kfin TechnologiesElara CapitalBuy1,280
Kfin TechnologiesNuvamaBuy1,450
Fortis HealthcareCitiBuy1,120
Fortis HealthcareGoldman SachsNeutral925
Fortis HealthcareNuvamaBuy1,145
Bharat Electronics (BEL)CitiBuy525
CE Info Systems (MapmyIndia)Elara CapitalBuy2,273
CE Info Systems (MapmyIndia)Goldman SachsNeutral1,900
PTC IndiaElara CapitalBuy210
Ahluwalia ContractsNuvamaBuy1,147
NBCC IndiaNuvamaBuy139
IPCA LaboratoriesNuvamaBuy1,750
Titagarh Rail SystemsNuvamaBuy1,061
Indigo PaintsNuvamaBuy1,505
Fine Organic IndustriesNuvamaBuy6,018

Kfin Technologies Share Price Target

  • Citi has reiterated its Buy rating on Kfin Technologies and revised the target price to Rs 1,385, compared with the earlier target of Rs 1,335.
  • Elara Capital has reiterated its Buy rating on KFin Technologies and maintained the target price at Rs 1,280.
  • Nuvama has maintained its Buy rating on KFin Technologies with a target price of Rs 1,450.

Fortis Healthcare Share Price Target

  • Citi has reiterated its Buy rating on Fortis Healthcare and maintained the target price at Rs 1,120.
  • Goldman Sachs has maintained its Neutral rating on Fortis Healthcare and kept the target price unchanged at Rs 925.
  • Nuvama has maintained its Buy rating on Fortis Healthcare and revised the target price to Rs 1,145, up from the earlier target of Rs 1,115.

Bharat Electronics (BEL) Share Price Target

Citi has maintained its Buy rating on Bharat Electronics (BEL) and kept the target price unchanged at Rs 525.

CE Info Systems Share Price Target

  • Elara Capital has reiterated its Buy rating on CE Info Systems (MapmyIndia) and revised the target price to Rs 2,273, reduced from the earlier target of Rs 2,551.
  • Goldman Sachs has assigned a Neutral rating to CE Info Systems and revised the target price to Rs 1,900, reduced from the earlier target of Rs 2,200.

PTC India Share Price Target

Elara Capital has reiterated its Buy rating on PTC India and maintained the target price at Rs 210.

Ahluwalia Contracts Share Price Target

Nuvama has maintained its Buy rating on Ahluwalia Contracts with a revised target price of Rs 1,147, compared with the earlier target of Rs 1,154.

NBCC Share Price Target

Nuvama has maintained its Buy rating on NBCC India and revised the target price to Rs 139, compared with the earlier target of Rs 146.

IPCA Laboratories Share Price Target

Nuvama has maintained its Buy rating on IPCA Laboratories and revised the target price to Rs 1,750, compared with the earlier target of Rs 1,610.

Titagarh Rail Systems Share Price Target

Nuvama has maintained its Buy rating on Titagarh Rail Systems and revised the target price to Rs 1,061, compared with the earlier target of Rs 1,088.

Indigo Paints Share Price Target

Nuvama has maintained its Buy rating on Indigo Paints with a target price of Rs 1,505.

Fine Organic Industries Share Price Target

Nuvama has maintained its Buy rating on Fine Organics with a target price of Rs 6,018.

(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)

Read Entire Article